

## [342] IMMUNE ONCOLOGY - SELECTIVE BLOCKING ANTIBODIES

**Aviv Boim<sup>1</sup>, <sup>1</sup> Tikcro Technologies**  
**Tikcro Technologies**

- **Investment Rational**  
Tikcro brings a novel approach to generate antibodies for immune-therapy cancer treatment. We promote an immunization technology which results with antibodies with a selective binding to pre-determined three-dimensional epitope structures. We have a first pre-clinical validation of a CTLA4 antibody. It shows impressive functionality over industry references and aims to broaden the clinical indications of a CTLA4 antibody treatment.
- **Business Strategy**  
We aim to promote our new CTLA4 antibody into a first clinical trial. We wish to translate strong in vitro and animal data into clinical value in multiple cancer indications. CTLA4 antibody treatment has synergies with several immune-related drugs which is a compelling avenue for partners. In another track, we develop antibodies for other immune pathways for cancer treatment.
- **Core Technology**  
We use a unique technology which "pin-points" an immunization process to generate antibodies which bind to desired discontinued epitopes by their 3D parameters. This technology mirrors three dimensional structures of epitopes of choice and triggers in animals a highly targeted immune response. Resulting antibodies would most likely otherwise not be selected.
- **Product Profile/Pipeline**  
Revenues for another existing CTLA4 antibody exceed \$1.0 Billion per annum for the treatment of Melanoma. We aim to broaden the targeted clinical indications. Expected operational milestones include manufacturing scale-up and a design of a first clinical trial. We look for collaborations to support treatment combinations with our CTLA4 antibody.
- **What's Next?**  
In 2018 we plan to conclude on-going pre-clinical development and to promote our CTLA4 antibody into a clinical stage targeting several cancer indications. Industry analysts project revenues for immune related antibodies of tens of US \$ Billion. We expect to bring our innovative technology and product candidate to this field. *[please refer to our periodically filings on [www.sec.gov](http://www.sec.gov) for a full description of our company and risks].*